New CIMZIA® (certolizumab pegol) data in moderate-to-severe plaque psoriasis and psoriatic arthritis presented at American Academy of Dermatology 2017 Annual Meeting

• Late-breaking, investigational 16-week data presented from the CIMPASI-1 and CIMPASI-2 trials showing CIMZIA demonstrated statistically and clinically significant improvements for patients with moderate-to-severe chronic plaque psoriasis
  
• Four-year data from the CIMZIA RAPID-PSA study showing long-term maintenance of improvement in the joint and skin manifestations of psoriatic arthritis regardless of prior exposure to an anti-TNF, or as monotherapy without concomitant use of disease modifying anti-rheumatic drugs (DMARDs)

ORLANDO, Fla., March 04, 2017 -- UCB (Euronext:UCB) and Dermira, Inc. (NASDAQ:DERM) today announced 16-week, investigational results from the CIMPASI-1 and CIMPASI-2 Phase 3 trials at the 75^th Annual Meeting of the American Academy of Dermatology (AAD) in Orlando, Florida.¹ Results from the trials showed that CIMZIA^® (certolizumab pegol) demonstrated significant improvements in patients with moderate-to-severe chronic plaque psoriasis versus placebo. In addition to previously reported co-primary endpoints, new data presented in an oral presentation at AAD showed the percentage of patients who achieved 90% or greater disease improvement from baseline, as measured by the Psoriasis Area and Severity Index (PASI 90). Additionally, data analyses from the RAPID-PsA Phase 3 study were presented evaluating the long-term effect of CIMZIA in adult patients with active psoriatic arthritis (PsA).

“The 16-week primary results from CIMPASI-1 and CIMPASI-2 showed that treatment with CIMZIA provided significant benefit to patients living with chronic plaque psoriasis, which is important given that the disease is historically difficult to treat and therefore requires multiple treatment options,” said Alice Gottlieb, M.D., Ph.D., Professor of Dermatology, Department of Dermatology, New York Medical College, at Metropolitan Hospital and lead presenter of the data.

“The CIMPASI-1 and CIMPASI-2 clinical results presented today support our belief that CIMZIA may one day benefit people living with moderate-to-severe plaque psoriasis,” said Luis Peña, chief development officer at Dermira. “We are committed to providing patients with access to a new treatment option for psoriasis that may also one day contribute to improvements in their overall quality of life.”

“We’re pleased to present the clinical results from CIMPASI-1, CIMPASI-2, and RAPID-PsA at AAD this year,” said Emmanuel Caeymaex, Head of Immunology and Executive Vice President at UCB, Immunology Patient Value Unit, UCB. “At UCB, we are driven foremost by providing value to patients, and these results demonstrate the breadth of our immunology portfolio for people living with plaque psoriasis and psoriatic arthritis. We look forward to continuing our partnership with Dermira to bring CIMZIA to these patients."

The results of the initial 16-week treatment period of CIMPASI-1 and CIMPASI-2 offer important insights for the potential use and the value of CIMZIA in adult patients with moderate to severe chronic plaque psoriasis. Researchers reported that CIMZIA showed clinically meaningful improvements in the PGA, PASI 75 and PASI 90 endpoints at week 16 compared to placebo at both treatment doses (400mg, 200mg).

Topline results from CIMPASI-1 and CIMPASI-2 were previously announced. The identically designed trials evaluated the percentage of patients who achieved a 75% or greater disease improvement from baseline as measured by the Psoriasis Area and Severity Index (PASI 75), as well as the percentage of patients achieving at least a two-point improvement on a five-point Physician’s Global Assessment (PGA) scale to a final score representing clear or almost clear skin, each compared with placebo, at week 16.²

Researchers reported that the most frequent adverse events (AEs) in CIMPASI-1 and CIMPASI-2 through week 16 were upper respiratory tract infections, and serious AEs were infrequent. The adverse event profile across both trials appeared consistent with the adverse event profiles observed with CIMZIA in other indications.² CIMZIA is not currently approved for the treatment of psoriasis by any regulatory authority worldwide.

CIMPASI-1 16-week Results¹

• A total of 234 patients with moderate-to-severe chronic plaque psoriasis were randomized in the CIMPASI-1 trial to one of three dosing arms—400 mg every two weeks (n=88), 400 mg at weeks 0, 2, and 4 followed by 200 mg every two weeks (n=95), or placebo every two weeks (n=51).
  
  
• At week 16, the response rate for patients who achieved a PASI 75 was 75.8% for patients receiving the 400 mg dose every two weeks and 66.5% for patients receiving the 200 mg dose every two weeks, compared to 6.5% for patients receiving placebo.
  
  
• The response rate for patients achieving at least a two-point improvement to a final score of clear or almost clear skin on the PGA scale at week 16 was 57.9% for the 400 mg dose-treated patients and 47.0% for the 200 mg dose-treated patients, compared to 4.2% for the patients receiving placebo.
   
• At week 16, the response rate for patients who achieved a PASI 90 was 43.6% for patients receiving the 400 mg dose every two weeks and 35.8% for patients receiving the 200 mg dose every two weeks, compared to 0.4% for the patients receiving placebo.

CIMPASI-2 16-week Results¹

• A total of 227 patients with moderate-to-severe chronic plaque psoriasis were randomized in the CIMPASI-2 trial to one of three dosing arms—400 mg every two weeks (n=87), 400 mg at weeks 0, 2, and 4 followed by 200 mg every two weeks (n=91), or placebo every two weeks (n=49).
   
• At week 16, the response rate for patients who achieved a PASI 75 was 82.6% for patients receiving the 400 mg dose every two weeks and 81.4% for patients receiving the 200 mg dose every two weeks, compared to 11.6% for the patients receiving placebo.
  
  
• The response rate for patients achieving at least a two-point improvement to a final score of clear or almost clear skin on the PGA scale at week 16 was 71.6% for the 400 mg dose-treated patients and 66.8% for the 200 mg dose-treated patients, compared to 2.0% for the patients receiving placebo.
   
• At week 16, the response rate for patients who achieved a PASI 90 was 55.4% for patients receiving the 400 mg dose every two weeks and 52.6% for patients receiving the 200 mg dose every two weeks, compared to 4.5% for the patients receiving placebo.           

Additional data reported from a key secondary endpoint also found that patients receiving the 400mg and 200 mg dose reported significant improvements in their quality of life compared to patients who received placebo only. CIMZIA showed a mean improvement from baseline in the Dermatology Life Quality Index (DLQI) score compared to placebo, at both doses in both the CIMPASI-1 (decrease of 10.2 at 400 mg and 9.3 at 200 mg vs. 3.3; p<0.001) and CIMPASI-2 (decrease of 10.0 at 400 mg and 10.4 at 200 mg vs. 3.8; p<0.001) clinical trials, at week 16.

A decrease in a patient’s DLQI score translates to overall improved satisfaction in the management of their skin condition. DLQI is a widely used and recognized quality of life measurement instrument frequently used across many dermatologic conditions.

RAPID-PsA Results^3,4,5

Additionally, three post-hoc data analyses from the RAPID-PsA four-year open label extension study were presented, providing insight into the long-term impact of CIMZIA on psoriatic arthritis (PsA) patients. RAPID-PsA is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of CIMZIA. The results of RAPID-PsA were:

• A total of 409 patients with onset active and progressive psoriatic arthritis (PsA) were randomized to one of three dosing arms – to CIMZIA 200 mg every two weeks (n=138), CIMZIA 400 mg every four weeks (n=135), or placebo (n=136) for 24 weeks, followed by dose blind to week 48, and open-label extension to week 216. All patients received a loading dose with CIMZIA 400 mg or placebo at weeks 0, 2, and 4.
   
• Eligible patients had adult onset active PsA ≥6 months’ duration as defined by the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria, active psoriatic lesions or a documented history of psoriasis, ≥3 tender and ≥3 swollen joints, erythrocyte sedimentation rate ≥28 mm/hr (Westergren) and/or C-reactive protein greater than the upper limit of normal, and failed ≥1 DMARD (nonbiologic or biologic).
   
• For extra-articular manifestations (EAMs) specifically, by week 24, a large proportion of patients with baseline involvement achieved total resolution of the respective EAM (nail psoriasis: 38.5%, enthesitis: 65.2%, dactylitis: 73.8%) Mean scores in all EAMs assessed showed improvements by week 12 and maintained to week 216 for patients completing the study.
   
• Patients with or without prior anti-TNF exposure experienced improvements in joint and skin manifestations that were maintained over four years. For skin outcomes, these improvements were maintained in patients with and without prior anti-TNF exposure. Additionally, for patients treated with CIMZIA^® both with and without concomitant DMARD use, efficacy was maintained over four years.

About Psoriasis

Psoriasis is a common, chronic, immune-mediated inflammatory disorder with primary involvement of the skin. It affects nearly three percent of the world’s population, or approximately 125 million people worldwide. The skin condition affects men and women of all ages and ethnicities. Psoriasis signs and symptoms can vary, but may include red patches of skin covered with silvery scales, dry, cracked skin that may bleed and thickened, pitted or ridged nails.⁶

About Psoriatic Arthritis

Psoriatic arthritis (PsA) is a condition involving joint inflammation (arthritis) that usually occurs in combination with a skin disorder called psoriasis. Signs and symptoms of PsA include stiff, painful joints with warmth and swelling in the joints and surrounding tissues. In most people with PsA, psoriasis appears before joint problems develop. In some cases, psoriatic arthritis develops prior to the skin changes. Left untreated PsA can be a disabling disease. PsA affects an estimated 3.4 to 8 per 100,000 people. Between 6 and 42 percent of people with psoriasis develop psoriatic arthritis. Psoriasis affects nearly three percent of the world’s population, or approximately 125 million people worldwide.^7,8

About Cimzia^® In the US
Cimzia^® is the only Fc-free, PEGylated anti-TNF (Tumor Necrosis Factor). Cimzia^® has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha.

Cimzia^® is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis, adults with active psoriatic arthritis (PsA), and adults with active ankylosing spondylitis (AS). In addition, it is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. See important safety information including risk of serious bacterial, viral and fungal infections and tuberculosis below.

Important Safety Information about Cimzia^® in the US

Risk of Serious Infections and Malignancy

Patients treated with Cimzia^® are at an increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Cimzia^® should be discontinued if a patient develops a serious infection or sepsis. Reported infections include:

• Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before Cimzia^® use and during therapy. Treatment for latent infection should be initiated prior to Cimzia^® use.
• Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.
• Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with Cimzia^® should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Cimzia^®, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which Cimzia^® is a member. Cimzia^® is not indicated for use in pediatric patients.

Patients treated with Cimzia^® are at an increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death. Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers. Patients have frequently presented with disseminated rather than localized disease.

Treatment with Cimzia^® should not be initiated in patients with an active infection, including clinically important localized infections. Cimzia^® should be discontinued if a patient develops a serious infection or sepsis. Patients greater than 65 years of age, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants (e.g., corticosteroids or methotrexate) may be at a greater risk of infection. Patients who develop a new infection during treatment with Cimzia^® should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for immunocompromised patients, and appropriate antimicrobial therapy should be initiated. Appropriate empiric antifungal therapy should also be considered while a diagnostic workup is performed for patients who develop a serious systemic illness and reside or travel in regions where mycoses are endemic.

Malignancies

During controlled and open-labeled portions of Cimzia^® studies of Crohn’s disease and other diseases, malignancies (excluding non-melanoma skin cancer) were observed at a rate of 0.5 per 100 patient-years among 4,650 Cimzia^®-treated patients versus a rate of 0.6 per 100 patient-years among 1,319 placebo-treated patients. In studies of Cimzia^® for Crohn’s disease and other investigational uses, there was one case of lymphoma among 2,657 Cimzia^®-treated patients and one case of Hodgkin lymphoma among 1,319 placebo-treated patients. In Cimzia^® RA clinical trials (placebo-controlled and open label), a total of three cases of lymphoma were observed among 2,367 patients. This is approximately 2-fold higher than expected in the general population. Patients with RA, particularly those with highly active disease, are at a higher risk for the development of lymphoma. The potential role of TNF blocker therapy in the development of malignancies is not known.

Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy ≤18 years of age), of which Cimzia^® is a member. Approximately half of the cases were lymphoma (including Hodgkin’s and non-Hodgkin’s lymphoma), while the other cases represented a variety of different malignancies and included rare malignancies associated with immunosuppression and malignancies not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants.

Cases of acute and chronic leukemia have been reported with TNF-blocker use. Even in the absence of TNF-blocker therapy, patients with RA may be at a higher risk (approximately 2-fold) than the general population for developing leukemia.

Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma that has a very aggressive disease course and is usually fatal, have been reported in patients treated with TNF blockers, including Cimzia^®. The majority of reported TNF blocker cases occurred in adolescent and young adult males with Crohn’s disease or ulcerative colitis. Almost all of these patients had received treatment with the immunosuppressants azathioprine and/or 6-mercaptopurine (6-MP) concomitantly with a TNF blocker at or prior to diagnosis. Carefully assess the risks and benefits of treatment with Cimzia^®, especially in these patient types.

Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF-antagonists, including Cimzia^®. Periodic skin examinations are recommended for all patients, particularly those with risk factors for skin cancer.

Heart Failure

Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers. Cimzia^® has not been formally studied in patients with CHF. Exercise caution when using Cimzia^® in patients who have heart failure and monitor them carefully.

Hypersensitivity

Symptoms compatible with hypersensitivity reactions, including angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria, have been reported rarely following Cimzia^® administration. Some of these reactions occurred after the first administration of Cimzia^®. If such reactions occur, discontinue further administration of Cimzia^® and institute appropriate therapy.

Hepatitis B Reactivation

Use of TNF blockers, including Cimzia^®, has been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus. Some cases have been fatal. Test patients for HBV infection before initiating treatment with Cimzia^®. Exercise caution in prescribing Cimzia^® for patients identified as carriers of HBV, with careful evaluation and monitoring prior to and during treatment. In patients who develop HBV reactivation, discontinue Cimzia^® and initiate effective anti-viral therapy with appropriate supportive treatment.

Neurologic Reactions

Use of TNF blockers, including Cimzia^®, has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease, including multiple sclerosis, and with peripheral demyelinating disease, including Guillain-Barré syndrome. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with Cimzia^®. Exercise caution in considering the use of Cimzia^® in patients with these disorders.

Hematologic Reactions

Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia (e.g., leukopenia, pancytopenia, thrombocytopenia) has been infrequently reported with Cimzia^®. Advise all patients to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g., persistent fever, bruising, bleeding, pallor) while on Cimzia^®. Consider discontinuation of Cimzia^® therapy in patients with confirmed significant hematologic abnormalities.

Drug Interactions

An increased risk of serious infections has been seen in clinical trials of other TNF blocking agents used in combination with anakinra or abatacept. Formal drug interaction studies have not been performed with rituximab or natalizumab; however, because of the nature of the adverse events seen with these combinations with TNF blocker therapy, similar toxicities may also result from the use of Cimzia^® in these combinations. Therefore, the combination of Cimzia^® with anakinra, abatacept, rituximab, or natalizumab is not recommended. Interference with certain coagulation assays has been detected in patients treated with Cimzia^®. There is no evidence that Cimzia^® therapy has an effect on in vivo coagulation. Cimzia^® may cause erroneously elevated aPTT assay results in patients without coagulation abnormalities.

Autoimmunity

Treatment with Cimzia^® may result in the formation of autoantibodies and, rarely, in the development of a lupus-like syndrome. Discontinue treatment if symptoms of lupus-like syndrome develop.

Immunizations

Do not administer live vaccines or live-attenuated vaccines concurrently with Cimzia^®.

Adverse Reactions

In controlled Crohn’s clinical trials, the most common adverse events that occurred in ≥5% of Cimzia^® patients (n=620) and more frequently than with placebo (n=614) were upper respiratory infection (20% Cimzia^®, 13% placebo), urinary tract infection (7% Cimzia^®, 6% placebo), and arthralgia (6% Cimzia^®, 4% placebo). The proportion of patients who discontinued treatment due to adverse reactions in the controlled clinical studies was 8% for Cimzia^® and 7% for placebo.

In controlled RA clinical trials, the most common adverse events that occurred in ≥3% of patients taking Cimzia^® 200 mg every other week with concomitant methotrexate (n=640) and more frequently than with placebo with concomitant methotrexate (n=324) were upper respiratory tract infection (6% Cimzia^®, 2% placebo), headache (5% Cimzia^®, 4% placebo), hypertension (5% Cimzia^®, 2% placebo), nasopharyngitis (5% Cimzia^®, 1% placebo), back pain (4% Cimzia^®, 1% placebo), pyrexia (3% Cimzia^®, 2% placebo), pharyngitis (3% Cimzia^®, 1% placebo), rash (3% Cimzia^®, 1% placebo), acute bronchitis (3% Cimzia^®, 1% placebo), fatigue (3% Cimzia^®, 2% placebo). Hypertensive adverse reactions were observed more frequently in patients receiving Cimzia^® than in controls. These adverse reactions occurred more frequently among patients with a baseline history of hypertension and among patients receiving concomitant corticosteroids and non-steroidal anti-inflammatory drugs. Patients receiving Cimzia^® 400 mg as monotherapy every 4 weeks in RA controlled clinical trials had similar adverse reactions to those patients receiving Cimzia^® 200 mg every other week. The proportion of patients who discontinued treatment due to adverse reactions in the controlled clinical studies was 5% for Cimzia® and 2.5% for placebo.

The safety profile for patients with Psoriatic Arthritis (PsA) treated with CIMZIA® was similar to the safety profile seen in patients with RA and previous experience with Cimzia®.

The safety profile for AS patients treated with Cimzia^® was similar to the safety profile seen in patients with RA.

For full prescribing information, please visit www.ucb.com

CIMZIA^® is a registered trademark of the UCB Group of Companies.

About Cimzia^® in the EU/EEA
In the EU, Cimzia^® in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active RA in adult patients inadequately responsive to disease-modifying anti-rheumatic drugs (DMARDs) including MTX.

Cimzia^® can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. CIMZIA^® in combination with MTX is also indicated for the treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs.

Cimzia^® has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with MTX.

Cimzia^®, in combination with MTX, is also indicated for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate. Cimzia^® can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.

Cimzia^® is also indicated in the EU for the treatment of adult patients with severe active axial spondyloarthritis (axSpA), comprising:

• Ankylosing spondylitis (AS) - adults with severe active AS who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).
• Axial spondyloarthritis (axSpA) without radiographic evidence of AS - adults with severe active axSpA without radiographic evidence of AS but with objective signs of inflammation by elevated C-reactive protein (CRP) and/or Magnetic Resonance Imaging (MRI) who have had an inadequate response to, or are intolerant to NSAIDs.⁴

Important Safety Information about Cimzia^® in the EU/EEA
Cimzia^® was studied in 4,049 patients with rheumatoid arthritis (RA) in controlled and open label trials for up to 92 months. The commonly reported adverse reactions (1-10%) in clinical trials with Cimzia^® and post-marketing were viral infections (includes herpes, papillomavirus, influenza), bacterial infections (including abscess), rash, headache (including migraine), asthaenia, leukopaenia (including lymphopaenia, neutropaenia), eosinophilic disorder, pain (any sites), pyrexia, sensory abnormalities, hypertension, pruritus (any sites), hepatitis (including hepatic enzyme increase), injection site reactions, and nausea. Serious adverse reactions include sepsis, opportunistic infections, tuberculosis, herpes zoster, lymphoma, leukaemia, solid organ tumours, angioneurotic oedema, cardiomyopathies (includes heart failure), ischemic coronary artery disorders, pancytopaenia, hypercoagulation (including thrombophlebitis, pulmonary embolism), cerebrovascular accident, vasculitis, hepatitis/hepatopathy (includes cirrhosis), and renal impairment/nephropathy (includes nephritis). In RA controlled clinical trials, 4.4% of patients discontinued taking Cimzia^® due to adverse events vs. 2.7% for placebo.

Cimzia^® is contraindicated in patients with hypersensitivity to the active substance or any of the excipients, active tuberculosis or other severe infections such as sepsis or opportunistic infections or moderate-to-severe heart failure.

Serious infections including sepsis, tuberculosis and opportunistic infections have been reported in patients receiving Cimzia^®. Some of these events have been fatal. Monitor patients closely for signs and symptoms of infections including tuberculosis before, during and after treatment with Cimzia^®. Treatment with Cimzia^® must not be initiated in patients with a clinically important active infection. If an infection develops, monitor carefully and stop Cimzia^® if infection becomes serious. Before initiation of therapy with Cimzia^®, all patients must be evaluated for both active and inactive (latent) tuberculosis infection. If active tuberculosis is diagnosed prior to or during treatment, Cimzia^® therapy must not be initiated and must be discontinued. If latent tuberculosis is diagnosed, appropriate anti-tuberculosis therapy must be started before initiating treatment with Cimzia^®. Patients should be instructed to seek medical advice if signs/symptoms (e.g. persistent cough, wasting/weight loss, low grade fever, listlessness) suggestive of tuberculosis occur during or after therapy with Cimzia^®.

Reactivation of hepatitis B has occurred in patients receiving a TNF-antagonist including Cimzia^® who are chronic carriers of the virus (i.e. surface antigen positive). Some cases have had a fatal outcome. Patients should be tested for HBV infection before initiating treatment with Cimzia^®. Carriers of HBV who require treatment with Cimzia^® should be closely monitored and in the case of HBV reactivation Cimzia^® should be stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.

TNF antagonists including Cimzia^® may increase the risk of new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease; of formation of autoantibodies and uncommonly of the development of a lupus-like syndrome; of severe hypersensitivity reactions. If a patient develops any of these adverse reactions, Cimzia^® should be discontinued and appropriate therapy instituted.

With the current knowledge, a possible risk for the development of lymphomas, leukaemia or other malignancies in patients treated with a TNF antagonist cannot be excluded. Rare cases of neurological disorders, including seizure disorder, neuritis and peripheral neuropathy, have been reported in patients treated with Cimzia^®.

Adverse reactions of the hematologic system, including medically significant cytopaenia, have been infrequently reported with Cimzia^®. Advise all patients to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g., persistent fever, bruising, bleeding, pallor) while on Cimzia^®. Consider discontinuation of Cimzia^® therapy in patients with confirmed significant haematological abnormalities.

The use of Cimzia^® in combination with anakinra or abatacept is not recommended due to a potential increased risk of serious infections. As no data are available, Cimzia^® should not be administered concurrently with live vaccines. The 14-day half-life of Cimzia^® should be taken into consideration if a surgical procedure is planned. A patient who requires surgery while on CIMZIA^® should be closely monitored for infections.

Cimzia^® was studied in 325 patients with active axial spondyloarthritis (axSpA) in a placebo-controlled clinical trial for up to 30 months and in 409 patients with psoriatic arthritis (PsA) in a placebo-controlled clinical trial for up to 30 months. The safety profile for axSpA and PsA patients treated with Cimzia^® was consistent with the safety profile in RA and previous experience with Cimzia^®.

Please consult the full prescribing information in relation to other side effects, full safety and prescribing information. European SmPC date of revision 15^th December 2016.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001037/WC500069763.pdf 

REFERENCES

1. Certolizumab Pegol Treatment for Chronic Plaque Psoriasis: 16-Week Primary Results from two Phase 3, Multicenter, Randomized, Placebo-Controlled Studies. Gottlieb, A., et al. Presented at the American Academy of Dermatology Annual Meeting in Orlando. March 4, 2017.
2. UCB Data on File.
3. Certolizumab Pegol is Associated with Long-Term Improvements in Extra-Articular Manifestations of Psoriatic Arthritis Over 4 Years of Treatment. Fitzgerald, O., et al. Presented at the American Academy of Dermatology Annual Meeting in Orlando. March 5, 2017.
4. The Efficacy of Certolizumab Pegol Over 4 Years in Psoriatic Arthritis Patients With and Without Concomitant Use of DMARDs. Walsh, J et. Presented at the American Academy of Dermatology Annual Meeting in Orlando. March 5, 2017.
5. The Effect of Certolizumab Pegol On Skin Manifestations Over 4 Years of Treatment in Psoriatic Arthritis Patients With and Without Prior Anti-TNF Exposure. Krhaish M., et al. Presented at the American Academy of Dermatology Annual Meeting in Orlando. March 5, 2017.
6. International Federation of Psoriasis Associations. Accessed February 14, 2017 at http://www.worldpsoriasisday.com/web/page.aspx?refid=130
7. Gladman, DD., et al. Psoriatic Arthritis: Epidemiology, Clinical Features, Course, and Outcome. Ann Rheum Dis, 2005; 64: ii14-ii17.
8. Ritchlin CT., et al. Treatment Recommendations for Psoriatic Arthritis. Ann Rheum Dis, 2009; 68: 1387-1394.

About Dermira

Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify and develop leading-edge medical dermatology programs. Dermira’s product pipeline includes three Phase 3 product candidates that could have a profound impact on the lives of patients: glycopyrronium tosylate (formerly DRM04), in development for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); CIMZIA® (certolizumab pegol), in development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; and olumacostat glasaretil, in development for the treatment of acne vulgaris. Dermira is headquartered in Menlo Park, Calif. For more information, please visit www.dermira.com.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com) and LinkedIn page (https://www.linkedin.com/company/dermira-inc-) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website and LinkedIn page in addition to following its SEC filings, press releases, public conference calls and webcasts.

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 700 people in approximately 40 countries, the company generated revenue of € 3.9 billion in 2015. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

Dermira Forward-Looking Statements
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. This press release contains forward-looking statements that involve substantial risks and uncertainties, including the statements that CIMZIA one day benefit patients living with moderate-to-severe plaque psoriasis and contribute to improvements in their overall quality of life.  These statements deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to the design, implementation and outcomes of Dermira’s clinical trials; the outcome of future discussions with regulatory authorities relating to the CIMZIA clinical program; Dermira’s dependence on third-party clinical research organizations, manufacturers and suppliers; and Dermira’s ability to continue to stay in compliance with applicable laws and regulations. You should refer to the section entitled “Risk Factors” set forth in Dermira’s Annual Report on Form 10-K, Dermira’s Quarterly Reports on Form 10-Q and other filings Dermira makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Dermira’s forward-looking statements. Furthermore, such forward-looking statements speak only as of the date of this press release. Dermira undertakes no obligation to publicly update any forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.

UCB Forward-Looking Statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations,  changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

Dermira Contacts:

Media:
Erica Jefferson 
Senior Director, Head of Corporate Communications 
650-421-7216 
[email protected]

Investors:
Andrew Guggenhime 
Chief Operating Officer and Chief Financial Officer 
650-421-7200 
[email protected]

Robert H. Uhl 
Westwicke Partners 
Managing Director 
858-356-5932 
[email protected]

UCB Contacts:

France Nivelle 
Global Communications, UCB
T +32.2.559.9178, [email protected]

Andrea Christopher,
Global Immunology Communications, UCB
T +1.404.483.7329, [email protected]

Laurent Schots
Media Relations, UCB 
T +32.2.559.92.64, [email protected]

Antje Witte         
Investor Relations, UCB
T +32.2.559.94.14, [email protected]

Isabelle Ghellynck,
Investor Relations, UCB
T +32.2.559.9588, [email protected]